NKTX · Nkarta, Inc.
AI read · Good for NKTX
The AI's read
The results suggest NKX019 may help people with myositis and systemic sclerosis, including patients who had tried other treatments. Safety findings also support the results: none of the 40 treated patients died or stopped treatment because of side effects. The evidence is still early. The strongest response counts came from small groups, and two lower-dose myositis patients later had increased disease activity and needed more treatment. This makes the results promising, but not proof that the therapy will work broadly.